Allergan, Inc.

Cell Therapeutics, Inc.

Other

Alcon, Inc.

Rhett M Schiffman

Chin-Ming Chang

James Nienyuan Chang

Joan-En Chang-Lin

R Scott Jordan

Chetan Pujara

Mayssa Attar

Michael R Robinson

James A Burke

Alazar N Ghebremeskel

Gregg Feinerman

Pamela S Barnett

Neil Barth

Richard S Graham

Ajay P Parashar

Sukhon Likitlersuang

Jie Shen

William F Kelly

Marina Bejanian

Anuradha V Gore

John T Trogden

June Chen

Adnan K Salameh

Jaya Giyanani

Devin F Welty

Eldon Q Farnes

Ronald Bradford

Andrea S Kim

Lukas Scheibler

Eldon Quinn Farnes

Scott M Whitcup

Walter L Tien

Aileen Morgan

John G Walt

Debbie D Mullins

Connie M Stucker

Wendy Blanda

Debbie Mullins

Connie Stucker

David Hollander

Gregg Feinermann

Linda Villanueva

David A Hollander

This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor

An ocular implant including a drug releasing element and having an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the Schlemm's canal portion being arranged and configured to be disposed within Schlemm's canal of the eye when the inlet portion is disposed in the anterior chamber.

Ocular implant and delivery system

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humour

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.

Non-irritating testosterone emulsions

Therapeutic methods including administration of cyclosporin to an eye of a mammal in combination with administration of a therapeutically active agent effective for treatment of a cancer to said mammal to treat an ocular condition associated with the use of said therapeutically active agent are disclosed herein.

Prevention and treatment of ocular side effects with a cyclosporin

Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.

Intracameral sustained release therapeutic agent implants

The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intraocular pressure and treatment of glaucoma.

Preservative free bimatoprost and timolol solutions

The present disclosure relates to methods of treatment or prevention of ocular conditions caused by treatment with certain therapeutically active agents. The methods can include administering a cyclosporine, an analog or derivative thereof, or a combination thereof to an eye of a mammal suffering from an ocular condition cased by treatment with certain therapeutically active agents, which can include a chemotherapy agent or an antiviral agent.

The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.

Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.

Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use

Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.

Cyclosporin compositions

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Enhanced bimatoprost ophthalmic solution

Growing community of inventors

Laguna Beach, CA, United States of America

Rhett M Schiffman